Roche launches R&D partnership with Lausanne universitiesMonday, 10 July 2017
EPFL, CHUV and the University of Lausanne have signed a 6-million franc partnership with Roche, the world’s largest biotechnology company. The aim is to accelerate the development of innovative therapies against cancer.
The University of Lausanne (UNIL), the Swiss Federal Institute of Technology Lausanne (EPFL) and the Lausanne University Hospital (CHUV) have teamed up with Roche to work on preclinical, clinical and translational research projects in specific areas of oncology. The focus will be on immuno-oncology and targeted therapies within the tumor microenvironment, which are “increasingly important pillars in the development of oncology therapies and among Lausanne and its institutions’ main strengths", said world-renowned specialist George Coukos, head of the UNIL-CHUV Oncology Department.
Joining forces for excellence in oncology
This partnership combines the respective strengths of the parties involved. UNIL, EPFL and CHUV bring cutting-edge skills in basic, translational and clinical research, as well as in bioengineering, immunoengineering and innovative technology. Roche, whose financial participation amounts to about 6 million francs over at least three years, offers an extensive expertise in the research and development of molecules.
"Roche's visionary commitment through this clinical and preclinical strategic alliance is an important step in the development of the Lake Geneva region as a region dedicated to excellence in oncology," said Professor Douglas Hanahan, head of the Swiss Institute for Experimental Cancer Research (ISREC), which is part of the EPFL School of Life Sciences.